BowTiedPepDoc

Former internal medicine physician, now dedicated to longevity medicine and helping patients optimize their healthspan through peptide therapeutics.

[BowTiedPepDoc @PeptidePusherDO]

Osteoporosis and osteopenia are not direct side effects of Ozempic or any of the GLP-1s. These conditions arise from long-term deficiencies in nutrients critical for bone health (e.g., calcium, vitamin D, vitamin k2, protein, etc.) and insufficient weight-bearing exercise. These medications are fantastic, but too many people want an easy way out, consuming minimal calories devoid of nutrients and sitting on the couch all day.

[David W @rn_flex]

@DrIngold @MichaelAlbertMD Non HDL-C and ApoB still dropping after 48 weeks is a fun trick and the % reductions of both match low-moderate statins

[Kurt Harris MD 🇺🇦🇮🇱 @radfugee]

Ozempic class of drugs, however, are basically a distilled and extremely direct way of affecting the part of your brain that regulates appetitive behavior such that a person who’s been obese for decades can eat the way naturally thin people who have never been obese do

[Robert Lufkin MD @robertlufkinmd]

Increasing GLP-1 effects on obesity.

Semaglutide (1 peptide) vs tirzepatide (2 peptides) vs retatrutide (3 peptides)

https://t.co/dLnsGueUjR

[ERM @Owner_X429]

Semaglutide (1 peptide) vs tirzepatide (2 peptides) vs retatrutide (3 peptides)# Obesity medical 🏥 therapies

[David W @rn_flex]

@BNordestgaard The Triumph Outcomes trials with retatrutide will be a good test of this, 5 year trial looking at cardiac and renal outcomes. It lowers ApoB, TRL-C, ApoC3, ANGPTL3/8, VLDL, LDL, triglycerides, and non HDL-C.

[Michael Weintraub, MD @MWeintraubMD]

#Tirzepatide in HFpEF and obesity shows significantly lower cardiovascular composite events compared to placebo ♥️ in the newly published #SUMMIT trial.

9.9% tirzepatide vs. 15.3% placebo in composite of death from cardiovascular cause or worsening heart failure🫀

Also the co-primary endpoint KCCQ-CSS quality of life questionnaire with significant improvement over placebo

This #SUMMIT trial follows the already published #semaglutide HFpEF and HFpEF-DM which also demonstrated reduced CV events and improved quality of life

Published today and the second tirzepatide trial in the @NEJM this week!

https://t.co/VVWWHyZftf

[Michael Weintraub, MD @MWeintraubMD]

Tirzepatide prevents progression to type 2 diabetes by 93% in those with prediabetes and obesity🤯

📉Weight loss of 19.7% was sustained over 3 years with the highest dose.

New trial results published in NEJM today

https://t.co/ZzQthJvQFx

[Jesse Morse, M.D. @DrJesseMorse]

@moregabagool123 @TonyBaeumler7 I know way to much about all the side effects of that stuff

I’m trying to live to 120, I’m not doing anything counter productive

Enclomiphene
Kissipeptin
T
PT-141
Epitalon
FOXO4-DRI
BPC-157
TB-4
TA-1
GHK-CU

That’s just the tip of the iceberg

[Abud Bakri MD @AbudBakri]

I can't wait to prescribe loads of BPC-157 once @RobertKennedyJr changes the regulatory environment

So many people would benefit as I have in their surgical recoveries

(under clinical supervisions, these peptides are much safer :) )

[Abud Bakri MD @AbudBakri]

I truly wish I could prescribe BPC-157 to many of my hospital patients

It's a complete shame that they are the people to likely benefit the most, but we can't even get a clear answer or good studies for $$ reasons

While the bros who are already pretty healthy are nose deep🤣

[Michael Weintraub, MD @MWeintraubMD]

We have data demonstrating GLP1 benefit in diabetic kidney disease, but what about non-diabetic kidney disease? 🤔

Enter the SMART trial which enrolled adults with BMI >27 and non-diabetic CKD and randomized to semaglutide vs. placebo

Baseline BMI 36, GFR 65, urine albumin to creatinine (UACR) ratio 251

⬇️51% reduction in UACR in semaglutuide by week 24

https://t.co/VmIalQwYAw

[BowTiedPepDoc @PeptidePusherDO]

@datarade Retatrutide is THE juggernaut. I’ve observed remarkable outcomes in patients terms of fat loss, muscle retention, triglyceride reduction, blood glucose control, BP reduction, obliteration of liver fat, and increased energy compared to semaglutide or tirzepatide.

[Kumar🇺🇸 @datarade]

Peptides will obliterate so much of prescription drug mayhem because they work.

Once Retatrutide is mainstreamed, it's game over for a high number of drugs in the big pharma portfolio.

Whether you like RFK or not, it's a net positive for America to have more peptides.

[Scott Isaacs @scottisaacsmd]

Weight loss with #retatrutide, #tirazepatide, and #semaglutide compared to placebo.
https://t.co/g1abmpmqHB

[Michael Weintraub, MD @MWeintraubMD]

New trial results🙏

Semaglutide demonstrates improvement in knee osteoarthritis pain in participants with obesity 🦴

407 adults with mean BMI 40.3 had had an improvement in the WOMAC pain score of -41.7 with 13.7% weight loss, compared to pain score improvement of -27.5 with 3.2% weight loss in the placebo group.

Published in NEJM today https://t.co/dUgNIdNyB4

[Michael Weintraub, MD @MWeintraubMD]

#Tirzepatide SURMOUNT-1 three year efficacy outcomes just presented at #ObesityWeek2024 👀

📉Sustained weight loss of 22.9% or an average 54lbs over 3 years

🔽94% reduction in risk of progression to diabetes.
Number Needed to Treat = 9 🤯

🫀Improvement in metabolic parameters

This is the longest trial duration studying tirzepatide to date

[David W @rn_flex]

Number needed to treat of NINE

For context, statins have an NNT between 60 and 250 for ASCVD prevention.

Let's start treating pre-diabetes just like we do diabetes. It's the least we can do to keep our patients healthy

[Dr Rob 🫀🩺 🇦🇺 @drhungo]

💉 Retatrutide | Lipids ❤️

Triple agonist 👉🏼 glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 & glucagon receptors

Highest dose (12mg)

🔸 24% weight ⤵️
🔸 41% ⤵️ in TG’s
🔸 22% ⤵️ in LDL-C
🔸 40% ⤵️ in TRL-C

Also👉🏼 ⤵️ average size of TRLPs & sLDL

🔎 Looks promising for CV risk ⤵️ 🤞🏼

🔗 https://t.co/uTjI0wWvvM

#MedTwitter #CardioTwitter @society_eas @ESC_Journals #FOAMed #MedEd @ProfSNicholls @ajnelson

[Beverly G. Tchang, MD @BevTchangMD]

So curious about the "improved lipid partitioning into adipocytes does not increase body fat or adiposity" -- where does it go???

Is there concomitant ⬆️triglyceride utilization in the adipocyte so that total mass stays the same? @DanielJDrucker @williamroell

#GIP #EASD2024